Sage Therapeutics
Stock Forecast, Prediction & Price Target
Sage Therapeutics (SAGE) stock Price Target by analysts
$13.6
Potential upside: 56.50%
Sage Therapeutics price prediction
What is Sage Therapeutics stock analysts` prediction?
Sage Therapeutics stock forecast: Based on 5 Wall Street analysts` predicted price targets for Sage Therapeutics in the last 3 months, the avarage price target is $13.6, with a high forecast of $NaN. The average price target represents a 56.50% change from the last price of $8.69.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Sage Therapeutics stock Price Target by analysts
Full breakdown of analysts given Sage Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Brian Abrahams RBC Capital | 33.33% 1/3 | 10 months ago | $4 -53.97% downside | $4.91 | StreetInsider | Previous targets (2) |
Yasmeen Rahimi Piper Sandler | 0% 0/2 | 11 months ago | $26 199.19% upside | $7.9 | StreetInsider | Previous targets (1) |
George Farmer Scotiabank | 0% 0/2 | 11 months ago | $14 61.10% upside | $8.48 | TheFly | Previous targets (1) |
Vamil Divan Mizuho Securities | 0% 0/2 | 11 months ago | $10 15.07% upside | $7.86 | StreetInsider | Previous targets (1) |
Douglas Tsao H.C. Wainwright | 0% 0/1 | 11 months ago | $14 61.10% upside | $8.48 | TheFly | Previous targets (0) |
Joon Lee Truist Financial | 0% 0/3 | about 1 year ago | $13 49.59% upside | $7.95 | TheFly | Previous targets (2) |
Sumant Kulkarni Canaccord Genuity | 0% 0/1 | about 1 year ago | $9 3.56% upside | $8.88 | TheFly | Previous targets (0) |
Joel Beatty Robert W. Baird | 0% 0/1 | over 1 year ago | $15 72.61% upside | $11.93 | TheFly | Previous targets (0) |
Joon Lee Truist Financial | 0% 0/3 | over 1 year ago | $18 107.13% upside | $13.58 | StreetInsider | Previous targets (2) |
George Farmer Scotiabank | 0% 0/2 | over 1 year ago | $19 118.64% upside | $12.57 | StreetInsider | Previous targets (1) |
Brian Abrahams RBC Capital | 33.33% 1/3 | over 1 year ago | $26 199.19% upside | $12.12 | StreetInsider | Previous targets (2) |
Salveen Richter Goldman Sachs | 0% 0/1 | over 1 year ago | $28 222.20% upside | $12.11 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | over 1 year ago | $17 95.62% upside | $12.57 | StreetInsider | Previous targets (1) |
Vamil Divan Mizuho Securities | 0% 0/2 | over 1 year ago | $20 130.14% upside | $12.11 | StreetInsider | Previous targets (1) |
Joon Lee Truist Financial | 0% 0/3 | over 1 year ago | $22 153.16% upside | $12.32 | StreetInsider | Previous targets (2) |
Unknown J.P. Morgan | N/A | almost 3 years ago | $60 590.44% upside | $40.99 | Benzinga | N/A |
Unknown Guggenheim | N/A | almost 3 years ago | $48 452.35% upside | $35.27 | Benzinga | N/A |
Yasmeen Rahimi Piper Sandler | 0% 0/2 | over 3 years ago | $100 1050.74% upside | $33.86 | Pulse 2.0 | Previous targets (1) |
Gary Nachman BMO Capital | 100% 1/1 | over 3 years ago | $48 452.35% upside | $36.65 | StreetInsider | Previous targets (0) |
Marc Goodman Leerink Partners | 100% 1/1 | over 3 years ago | $50 475.37% upside | $34.71 | TipRanks Contributor | Previous targets (0) |
Brian Abrahams RBC Capital | 33.33% 1/3 | over 3 years ago | $37 325.77% upside | $34.71 | TipRanks Contributor | Previous targets (2) |
Paul Matteis Stifel Nicolaus | 0% 0/1 | over 3 years ago | $58 567.43% upside | $34.71 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | over 3 years ago | $74 751.55% upside | $33.58 | StreetInsider | Previous targets (1) |
Yatin Suneja Guggenheim | 100% 1/1 | almost 4 years ago | $55 532.91% upside | $43.57 | TheFly | Previous targets (0) |
Akash Tewari Jefferies | 100% 1/1 | almost 4 years ago | $50 475.37% upside | $45.64 | TheFly | Previous targets (0) |
Laura Chico Wedbush | 0% 0/1 | about 4 years ago | $80 820.59% upside | $41.76 | StreetInsider | Previous targets (0) |
Neena Bitritto-Garg Citigroup | 0% 0/1 | over 4 years ago | $68 682.50% upside | $54.88 | TheFly | Previous targets (0) |
Ritu Baral Cowen & Co. | 0% 0/1 | over 4 years ago | $105 1108.28% upside | $58.8 | StreetInsider | Previous targets (0) |
Sage Therapeutics Financial Estimates
Sage Therapeutics Revenue Estimates
Sage Therapeutics EBITDA Estimates
Sage Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $6.30M N/A | $7.68M 21.84% | $86.45M 1024.83% | Avg: $125.24M Low: $41.78M High: $466.34M avg. 44.86% | Avg: $275.46M Low: $124.82M High: $950.06M avg. 119.94% | Avg: $428.55M Low: $194.19M High: $1.47B avg. 55.57% | Avg: $660.99M Low: $299.52M High: $2.27B avg. 54.23% |
Net Income
% change YoY
| $-450.82M N/A | $-503.26M -11.63% | $-541.48M -7.59% | Avg: $-325.83M Low: $-450.56M High: $214.81M avg. 39.82% | Avg: $-201.29M Low: $-433.21M High: $722.82M avg. 38.22% | Avg: $-69.21M Low: $-289.55M High: $-20.00M avg. 65.61% | Avg: $59.33M Low: $17.15M High: $248.24M avg. 185.73% |
EBITDA
% change YoY
| $-460.90M N/A | $-546.98M -18.67% | $-545.07M 0.35% | Avg: $-85.54M Low: $-318.52M High: $-28.54M avg. 84.30% | Avg: $-188.14M Low: $-648.91M High: $-85.25M avg. -119.94% | Avg: $-292.70M Low: $-1.00B High: $-132.64M avg. -55.57% | Avg: $-451.47M Low: $-1.55B High: $-204.58M avg. -54.23% |
EPS
% change YoY
| -$7.68 N/A | -$8.49 -10.54% | -$9.05 -6.59% | Avg: -$5.14 Low: -$7.53 High: $3.59 avg. 43.25% | Avg: -$2.93 Low: -$7.24 High: $12.08 avg. 42.87% | Avg: -$1.16 Low: -$4.84 High: -$0.33 avg. 60.57% | Avg: $0.99 Low: $0.29 High: $4.15 avg. 185.73% |
Operating Expenses
% change YoY
| $466.66M N/A | $553.86M 18.68% | $664.14M 19.91% | Avg: $2.81B Low: $939.49M High: $10.48B avg. 323.97% | Avg: $6.19B Low: $2.80B High: $21.36B avg. 119.94% | Avg: $9.63B Low: $4.36B High: $33.23B avg. 55.57% | Avg: $14.86B Low: $6.73B High: $51.25B avg. 54.23% |
FAQ
What is Sage Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 82.35% in 2025-2028.
We have gathered data from 17 analysts. Their low estimate is -450.56M, average is -325.83M and high is 214.81M.
What is Sage Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 68.65% in 2025-2028.
We have gathered data from 16 analysts. Their low revenue estimate is $41.78M, average is $125.24M and high is $466.34M.
What is Sage Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 83.10% in 2025-2028.
We have gathered data from 17 analysts. Their low earnings per share estimate is -$7.53, average is -$5.14 and high is $3.59.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering Sage Therapeutics stock. The most successful analyst is Brian Abrahams whose win rate is 33.33%. He has correctly predicted 1/3 price targets.